Medicine

Luca Richeldi

MD, PhD

Primary position:
Professor of Respiratory Medicine, Chair of Interstitial Lung Disease

Background

The University of Southampton

Born and bred in Modena, northern Italy, Luca Richeldi obtained his MD degree from the School of Medicine of the University of Modena in 1988. During his PhD program in Rome, he developed a scientific interest in the area of interstitial lung diseases (ILD), a group comprising several acute and chronic lung disorders, characterized by a poor prognosis and the lack of effective treatments so far. Over the following years, Luca continued to be active in this field through international collaborations and participating in different studies dealing with diagnosis and treatment of ILD, with a particular interest for idiopathic pulmonary fibrosis (IPF), the most common and most lethal among all ILD. In 2005, as Associate Professor of Respiratory Medicine at the University Hospital of Modena, he founded and led the Centre for Rare Lung Disease.

His research activity started with a study exploring the genetic susceptibility factors involved in the development of a rare occupational form of progressive ILD, chronic beryllium disease. This led to the publication in Science of the association between a single genetic polymorphism and the disease. The interest for fibrotic lung disorders continued with the study of the effects of pharmacologic treatments in IPF. By using the methodologies of the evidence-based medicine and the statistical tool of meta-analysis, Luca published, as leading author, two Cochrane systematic reviews, critically assessing the low level of evidence for pharmacologic treatments empirically used until then. He has also been involved in the production of evidence-based international guidelines, endorsed by all major international respiratory scientific societies, focusing on the management of patients with IPF and the classification of idiopathic interstitial pneumonias. These documents form the basis for the current diagnostic and therapeutic management of patients with ILD and for the design of randomized clinical trials in this rapidly expanding area of respiratory medicine. More recently, Luca led the publication of one of the most promising phase II clinical trials in IPF, published in The New England Journal of Medicine. He also had an interest in lung infections, particularly tuberculosis. In this field he contributed to the development and the evaluation of a new generation of diagnostic tests for latent tuberculosis: these results were published as leading author in The Lancet. He is on the editorial board of the American Journal of Respiratory and Critical Care Medicine and is an associate editor for the European Respiratory Journal. Luca is member of the Fleischner Society.

Appointments held
  • Associate Professor of Respiratory Medicine, University of Modena and Reggio Emilia (Italy)
  • Director of the Centre for Rare Lung Diseases, University Hospital of Modena (Italy)
Professor Luca Richeldi's photo

Publications

The University of Southampton's electronic library (e-prints)

Article

Richeldi, Luca, Cottin, Vincent, Flaherty, Kevin R., Kolb, Martin, Inoue, Yoshikazu, Raghu, Ganesh, Taniguchi, Hiroyuki, Hansell, David M, Nicholson, Andrew G., Le Maulf, Florence, Stowasser, Susanne and Collard, Harold R. (2014) Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 108, (7), 1023-1030. (doi:10.1016/j.rmed.2014.04.011 ). (PMID:24834811).
Ley, Brett, Elicker, Brett M., Hartman, Thomas E., Ryerson, Christopher J., Vittinghoff, Eric, Ryu, Jay H., Lee, Joyce S., Jones, Kirk D., Richeldi, Luca, King, Talmadge E. and Collard, Harold R. (2014) Idiopathic pulmonary fibrosis: CT and risk of death. Radiology , 130216. (doi:10.1148/radiol.14130216 ). (PMID:24927326). (In Press).
Richeldi, Luca, du Bois, Roland M., Raghu, Ganesh, Azuma, Arata, Brown, Kevin K., Costabel, Ulrich, Cottin, Vincent, Flaherty, Kevin R., Hansell, David M., Inoue, Yoshikazu, Kim, Dong Soon, Kolb, Martin, Nicholson, Andrew G., Noble, Paul W., Selman, Moisés, Taniguchi, Hiroyuki, Brun, Michèle, Le Maulf, Florence, Girard, Mannaïg, Stowasser, Susanne, Schlenker-Herceg, Rozsa, Disse, Bernd and Collard, Harold R. (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. New England Journal of Medicine, 370, (22), 2071-2082. (doi:10.1056/NEJMoa1402584). (PMID:24836310).
Jaffar, Jade , Unger, Sofia , Corte, Tamera J., Keller, Michael , Wolters, Paul J., Richeldi, Luca, Cerri, Stefania , Prêle, Cecilia M., Hansbro, Philip M., Argraves, William Scott, Oliver, Rema A., Oliver, Brian G., Black, Judith L. and Burgess, Janette K. (2014) Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis. Chest (doi:10.1378/chest.13-2688 ). (PMID:24832167).
Saketkoo, Lesley Ann, Mittoo, Shikha, Huscher, Dörte, Khanna, Dinesh, Dellaripa, Paul F., Distler, Oliver, Flaherty, Kevin R., Frankel, Sid, Oddis, Chester V., Denton, Christopher P., Fischer, Aryeh, Kowal-Bielecka, Otylia M., LeSage, Daphne, Merkel, Peter A., Phillips, Kristine, Pittrow, David, Swigris, Jeffrey, Antoniou, Katerina, Baughman, Robert P., Castelino, Flavia V., Christmann, Romy B., Christopher-Stine, Lisa, Collard, Harold R., Cottin, Vincent, Danoff, Sonye, Highland, Kristin B., Hummers, Laura, Shah, Ami A., Kim, Dong Soon, Lynch, David A., Miller, Frederick W., Proudman, Susanna M., Richeldi, Luca, Ryu, Jay H., Sandorfi, Nora, Sarver, Catherine, Wells, Athol U., Strand, Vibeke, Matteson, Eric L., Brown, Kevin K. and Seibold, James R. (2014) Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax, 69, (5), 428-436. (doi:10.1136/thoraxjnl-2013-204202 ).
Jones, Mark G. and Richeldi, Luca (2014) Air pollution and acute exacerbations of idiopathic pulmonary fibrosis: back to miasma? European Respiratory Journal, 43, (4), 956-959. (doi:10.1183/09031936.00204213). (PMID:24687665).
Fischer, Aryeh and Richeldi, Luca (2014) Cross-disciplinary collaboration in connective tissue disease-related lung disease. Seminars in Respiratory and Critical Care Medicine, 35, (2), 159-165. (doi:10.1055/s-0034-1371530). (PMID:24668532).
Saketkoo, Lesley Ann, Mittoo, Shikha, Frankel, Sid, LeSage, Daphne, Sarver, Catherine, Phillips, Kristine, Strand, Vibeke, Matteson, Eric L. and Richeldi, Luca (2014) Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases. The Journal of Rheumatology, 41, (4), 792-798. (doi:10.3899/jrheum.131251). (PMID:24488412).
Cottin, Vincent and Richeldi, Luca (2014) Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment. European Respiratory Review, 23, (131), 106-110. (doi:10.1183/09059180.00008613). (PMID:24591667).
Jones, Mark G., Fletcher, Sophie and Richeldi, Luca (2013) Idiopathic pulmonary fibrosis: recent trials and current drug therapy. Respiration, 86, (5), 353-363. (doi:10.1159/000356958). (PMID:24296982).
Travis, William D., Costabel, Ulrich, Hansell, David M., King, Talmadge E., Lynch, David A., Nicholson, Andrew G., Ryerson, Christopher J., Ryu, Jay H., Selman, Moisés, Wells, Athol U., Behr, Jurgen, Bouros, Demosthenes, Brown, Kevin K., Colby, Thomas V., Collard, Harold R., Cordeiro, Carlos Robalo, Cottin, Vincent, Crestani, Bruno, Drent, Marjolein, Dudden, Rosalind F., Egan, Jim, Flaherty, Kevin, Hogaboam, Cory, Inoue, Yoshikazu, Johkoh, Takeshi, Kim, Dong Soon, Kitaichi, Masanori, Loyd, James, Martinez, Fernando J., Myers, Jeffrey, Protzko, Shandra, Raghu, Ganesh, Richeldi, Luca, Sverzellati, Nicola, Swigris, Jeffrey and Valeyre, Dominique (2013) An official American thoracic society/European respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. American Journal of Respiratory and Critical Care Medicine, 188, (6), 733-748. (doi:10.1164/rccm.201308-1483ST). (PMID:24032382).
Ryerson, Christopher J., Urbania, Thomas H., Richeldi, Luca, Mooney, Joshua J., Lee, Joyce S., Jones, Kirk D., Elicker, Brett M., Koth, Laura L., King, Talmadge E., Wolters, Paul J. and Collard, Harold R. (2013) Prevalence and prognosis of unclassifiable interstitial lung disease. European Respiratory Journal, 42, (3), 750-757. (doi:10.1183/09031936.00131912). (PMID:23222877).
Richeldi, Luca, Collard, Harold R., du Bois, Roland M., Jenkins, Gisli, Kolb, Martin, Maher, Toby M., Raghu, Ganesh, Vancheri, Carlo and Laurent, Geoffrey J. (2013) Mapping the future for pulmonary fibrosis: report from the 17th international colloquium on lung and airway fibrosis. European Respiratory Journal, 42, (1), 230-238. (doi:10.1183/09031936.00038613). (PMID:23682111).
Collard, Harold R., Yow, Eric, Richeldi, Luca, Anstrom, Kevin J. and Glazer, Craig (2013) Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respiratory Research, 14, 73. (doi:10.1186/1465-9921-14-73). (PMID:23848435).
Richeldi, Luca (2013) Idiopathic pulmonary fibrosis: current challenges and future perspectives. European Respiratory Review, 22, (128), 103-105. (doi:10.1183/09059180.00001413). (PMID:23728863).
Raghu, Ganesh, Behr, Juergen, Brown, Kevin K., Egan, Jim J., Kawut, Steven M., Flaherty, Kevin R., Martinez, Fernando J., Nathan, Steven D., Wells, Athol U., Collard, Harold R., Costabel, Ulrich, Richeldi, Luca, de Andrade, Joao, Khalil, Nasreen, Morrison, Lake D., Lederer, David J., Shao, Lixin, Li, Xiaoming, Pedersen, Patty S., Montgomery, A. Bruce, Chien, Jason W. and O’Riordan, Thomas G. (2013) Treatment of idiopathic pulmonary fibrosis with ambrisentan: a randomized trial. Annals of Internal Medicine, 158, (9), 641-649. (doi:10.7326/0003-4819-158-9-201305070-00003). (PMID:23648946).
Behr, Jürgen and Richeldi, Luca (2013) Recommendations on treatment for IPF. Respiratory Research, 14, supplement 1, S6. (doi:10.1186/1465-9921-14-S1-S6). (PMID:23734936).
Richeldi, Luca (2013) Clinical trials of investigational agents for IPF: a review of a Cochrane report. Respiratory Research, 14, supplement 1, S4. (doi:10.1186/1465-9921-14-S1-S4). (PMID:23734867).
Costabel, U., Albera, C., Behr, J., Cottin, V., Guenther, A. and Richeldi, L. (2013) Idiopathic pulmonary fibrosis in 2011: key updates on guidelines and therapeutics. Respiratory Research, 14, supplement 1, S1. (doi:10.1186/1465-9921-14-S1-S1). (PMID:22607134).
Lee, Joyce S., Kim, Eunice J., Lynch, Kara L., Elicker, Brett, Ryerson, Christopher J., Katsumoto, Tamiko R., Shum, Anthony K., Wolters, Paul J., Cerri, Stefania, Richeldi, Luca, Jones, Kirk D., King, Talmadge E. and Collard, Harold R. (2013) Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. Respiratory Medicine, 107, (2), 249-255. (doi:10.1016/j.rmed.2012.10.018). (PMID:23186614).
Colaci, Michele, Giuggioli, Dilia, Sebastiani, Marco, Manfredi, Andreina, Vacchi, Caterina, Spagnolo, Paolo, Cerri, Stefania, Luppi, Fabrizio, Richeldi, Luca and Ferri, Clodoveo (2013) Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. Autoimmunity Reviews, 12, (3), 374-379. (doi:10.1016/j.autrev.2012.06.003). (PMID:22743031).
Spagnolo, Paolo, Tonelli, Roberto, Cocconcelli, Elisabetta, Stefani, Alessandro and Richeldi, Luca (2012) Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges. Multidisciplinary respiratory medicine, 7, (1), 42. (doi:10.1186/2049-6958-7-42). (PMID:23146172).
Wells, Athol U., Behr, Juergen, Costabel, Ulrich, Cottin, Vincent, Poletti, Venerino and Richeldi, Luca (2012) Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. Thorax, 67, (11), 938-940. (doi:10.1136/thoraxjnl-2012-202580). (PMID:23345573).
Spagnolo, Paolo, Luppi, Fabrizio, Cerri, Stefania and Richeldi, Luca (2012) Genetic testing in diffuse parenchymal lung disease. Orphanet Journal of Rare Diseases, 7, 79. (doi:10.1186/1750-1172-7-79). (PMID:23075428).
du Bois, Roland M., Nathan, Steven D., Richeldi, Luca, Schwarz, Marvin I. and Noble, Paul W. (2012) Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials. American Journal of Respiratory and Critical Care Medicine, 186, (8), 712-715. (doi:10.1164/rccm.201206-1010PP). (PMID:22798316).
Luppi, Fabrizio, Spagnolo, Paolo, Cerri, Stefania and Richeldi, Luca (2012) The big clinical trials in idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 18, (5), 428-432. (doi:10.1097/MCP.0b013e3283567ff9). (PMID:22759771).
Richeldi, Luca (2012) Treating idiopathic pulmonary fibrosis: current opportunities and future challenges. The Clinical Respiratory Journal, 6, (3), 129-130. (doi:10.1111/j.1752-699X.2012.00303.x). (PMID:22697263).
Blasi, Francesco, Bocchino, Marialuisa, Di Marco, Fabiano, Richeldi, Luca and Aliberti, Stefano (2012) The role of biomarkers in low respiratory tract infections. European Journal of Internal Medicine, 23, (5), 429-435. (doi:10.1016/j.ejim.2012.05.002). (PMID:22726371).
Richeldi, Luca (2012) Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis. European Respiratory Review, 21, (124), 147-151. (doi:10.1183/09059180.00000912). (PMID:22654087).
Richeldi, L., Ryerson, C.J., Lee, J.S., Wolters, P.J., Koth, L.L., Ley, B., Elicker, B.M., Jones, K.D. , King, T.E. Jr, Ryu, JH and Collard, H.R. (2012) Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax, 67, (5), 407-411. (doi:10.1136/thoraxjnl-2011-201184 ). (PMID:22426899).
Cerri, Stefania, Spagnolo, Paolo, Luppi, Fabrizio and Richeldi, Luca (2012) Management of idiopathic pulmonary fibrosis. Clinics in Chest Medicine, 33, (1), 85-94. (doi:10.1016/j.ccm.2011.11.005). (PMID:22365248).
Spagnolo, Paolo, Luppi, Fabrizio, Roversi, Pietro, Cerri, Stefania, Fabbri, Leonardo Michele and Richeldi, Luca (2012) Sarcoidosis: challenging diagnostic aspects of an old disease. The American Journal of Medicine, 125, (2), 118-125. (doi:10.1016/j.amjmed.2011.06.003). (PMID:22269612).
Richeldi, L., Costabel, U., Selman, M., Kim, D.S., Hansell, D.M., Nicholson, A.G., Brown, K.K., Flaherty, K.R., Noble, P.W., Raghu, G., Brun, M., Gupta, A., Juhel, N., Kluglich, M. and du Bois, R.M. (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. New England Journal of Medicine, 365, (12), 1079-1087. (doi:10.1056/NEJMoa1103690). (PMID:21992121).
Losi, M., Bergamini, B.M., Venturelli, C., Del Giovane, C., Sighinolfi, G., Rumpaneisi, F. and Richeldi, L. (2011) Tuberculosis infection in foreign-born children: a screening survey based on skin and blood testing. The International Journal of Tuberculosis and Lung Disease, 15, (9), 1182-1184. (doi:10.5588/ijtld.10.0736). (PMID:21943842).
Richeldi, Luca and du Bois, Roland M. (2011) Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program. Expert Review of Respiratory Medicine, 5, (4), 473-481. (doi:10.1586/ers.11.52). (PMID:21859266).
Noble, Paul W., Richeldi, Luca and Kaminski, Naftali (2011) End of an ERA: lessons from negative clinical trials in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine, 184, (1), 4-5. (doi:10.1164/rccm.201105-0813ED). (PMID:21474646).
Richeldi, Luca, Yasothan, Uma and Kirkpatrick, Peter (2011) Pirfenidone. Nature Reviews: Drug Discovery, 10, (7), 489-490. (PMID:21837822).
Luppi, F., Covi, M., Velluti, G., Spagnolo, P., Fabbri, L.M. and Richeldi, L. (2011) Co-trimoxazole effect on human alveolar macrophages of AIDS patients. Journal of Biological Regulators & Homeostatic Agents, 25, (3), 461-464. (PMID:22023771).
Kolb, Martin R.J. and Richeldi, Luca (2011) Viruses and acute exacerbations of idiopathic pulmonary fibrosis: rest in peace? American Journal of Respiratory and Critical Care Medicine, 183, (12), 1583-1584. (doi:10.1164/rccm.201102-0326ED). (PMID:21693713).
Selman, Moisés, Pardo, Annie, Richeldi, Luca and Cerri, Stefania (2011) Emerging drugs for idiopathic pulmonary fibrosis. Expert Opinion on Emerging Drugs, 16, (2), 341-362. (doi:10.1517/14728214.2011.565049). (PMID:21410428).
Ruhwald, Morten, Dominguez, Jose, Latorre, Irene, Losi, Monica, Richeldi, Luca, Pasticci, Maria Bruna, Mazzolla, Rosanna, Goletti, Delia, Butera, Ornella, Bruchfeld, Judith, Gaines, Hans, Gerogianni, Irini, Tuuminen, Tamara, Ferrara, Giovanni, Eugen-Olsen, Jesper and Ravn, Pernille (2011) A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis. Tuberculosis, 91, (3), 260-267. (doi:10.1016/j.tube.2011.01.001). (PMID:21459676).
Losi, M., Bocchino, M., Matarese, A., Bellofiore, B., Roversi, P., Rumpianesi, F., Alma, M.G., Chiaradonna, P., Del Giovane, C., Altieri, A.M., Richeldi, L. and Sanduzzi, A. (2011) Role of the quantiferon-TB test in ruling out pleural tuberculosis: a multi-centre study. International Journal of Immunopathology and Pharmacology, 24, (1), 159-165. (PMID:21496398).
Raghu, G., Collard, H.R., Egan, J.J., Martinez, F.J., Behr, J., Brown, K.K., Colby, T.V., Cordier, J.F., Flaherty, K.R., Lasky, J.A., Lynch, D.A., Ryu, J.H., Swigris, J.J., Wells, A.U., Ancochea, J., Bouros, D., Carvalho, C., Costabel, U., Ebina, M., Hansell, D.M., Johkoh, T., Kim, D.S., King, T.E. Jr., Kondoh, Y., Myers, J., Muller, N.L., Nicholson, A.G., Richeldi, L., Selman, M., Dudden, R.F., Griss, B.S., Protzko, S.L. and Schünemann, H.J. (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. American Journal of Respiratory and Critical Care Medicine, 183, (6), 788-824. (doi:10.1164/rccm.2009-040GL ). (PMID:21471066).
Rossi, G., Tironi, A., Dore, R., Nannini, N., Mengoli, M.C., Bertolani, M. and Richeldi, L. (2010) Pulmonary eosinophilic infiltrates. Pathologica, 102, (6), 537-546. (PMID:21428117).
Richeldi, Luca (2010) Role of in vitro tests in the diagnosis of latent tubercular infections. Giornale italiano di medicina del lavoro ed ergonomia, 32, (3), 269-272. (PMID:21061708).
Spagnolo, P., Zeuzem, S., Richeldi, L. and du Bois, R.M. (2010) The complex interrelationships between chronic lung and liver disease: a review. Journal of Viral Hepatitis, 17, (6), 381-390. (doi:10.1111/j.1365-2893.2010.01307.x). (PMID:20384964).
Colaci, M., Sebastiani, M., Giuggioli, D., Manfredi, A., Spagnolo, P., Luppi, F., Richeldi, L. and Ferri, C. (2010) Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis. Scandinavian Journal of Rheumatology, 39, (2), 155-159. (doi:10.3109/03009740903270581). (PMID:20059446).
Luppi, Fabrizio, Beghé, Bianca and Richeldi, Luca (2010) Acute exacerbations of chronic obstructive pulmonary disease: are antibiotics needed? American Journal of Respiratory and Critical Care Medicine, 181, (2), 102-103. (doi:10.1164/rccm.200911-1668ED). (PMID:19875685).
Spagnolo, P., Del Giovane , C., Luppi, F., Cerri, S., Balduzzi, S., Walters, E.H., D'Amico, R. and Richeldi, L. (2010) Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Systematic Review, 9, CD003134.. (doi:10.1002/14651858.CD003134.pub2). (PMID:20824834).
Ferrara, Giovanni, Losi, Monica, Fabbri, Leonardo M., Migliori, Giovanni B., Richeldi, Luca and Casali, Lucio (2009) Exploring the immune response against Mycobacterium tuberculosis for a better diagnosis of the infection. Archivum Immunologiae et Therapiae Experimentalis, 57, (6), 425-433. (doi:10.1007/s00005-009-0050-9). (PMID:19866341).
Jafari, Claudia, Thijsen, Steven, Sotgiu, Giovanni, Goletti, Delia, Domínguez Benítez, José Antonio, Losi, Monica, Eberhardt, Ralf, Kirsten, Detlef, Kalsdorf, Barbara, Bossink, Aik, Latorre, Irene, Migliori, Giovanni B., Strassburg, Alan, Winteroll, Susanne, Greinert, Ulf, Richeldi, Luca, Ernst, Martin and Lange, Christoph (2009) Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup study. American Journal of Respiratory and Critical Care Medicine, 180, (7), 666-673. (doi:10.1164/rccm.200904-0557OC). (PMID:19590020).
Richeldi, Luca (2009) Diagnosing latent tuberculosis infection: guess who's coming to dinner? American Journal of Respiratory and Critical Care Medicine, 180, (1), 1-2. (doi:10.1164/rccm.200904-0562ED). (PMID:19342414).
Luppi, F., Losi, M., D'Amico, R., Fabbri, L.M. and Richeldi, L. (2009) Endogenous blood maximal interferon-gamma production may predict response to interferon-gamma 1beta treatment in patients with idiopathic pulmonary fibrosis. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG / World Association of Sarcoidosis and Other Granulomatous Disorders, 26, (1), 64-68. (PMID:19960790).
Ferrara, G., Losi, M., D'Amico, R., Cagarelli, R., Pezzi, A.M., Meacci, M., Meccugni, B., Marchetti Dori, I., Rumpianesi, F., Roversi, P., Casali, L., Fabbri, L.M. and Richeldi, L. (2009) Interferon-gamma-release assays detect recent tuberculosis re-infection in elderly contacts. International Journal of Immunopathology and Pharmacology, 22, (3), 669-677. (PMID:19822083).
Richeldi, L., Losi, M., D'Amico, R., Luppi, M., Ferrari, A., Mussini, C., Codeluppi, M., Cocchi, S., Prati, F., Paci, V., Meacci, M., Meccugni, B., Rumpianesi, F., Roversi, P., Ceri, S., Luppi, F., Ferrara, G., Latorre, I., Gerunda, G.E., Torelli, G., Esposito, R. and Fabbri, L.M. (2009) Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest, 136, (1), 198-204. (doi:10.1378/chest.08-2575). (PMID:19318676).
Bergamini, Barbara Maria, Losi, Monica, Vaienti, Francesca, D'Amico, Roberto, Meccugni, Barbara, Meacci, Marisa, De Giovanni, Donatella, Rumpianesi, Fabio, Fabbri, Leonardo M., Balli, Fiorella and Richeldi, Luca (2009) Performance of commercial blood tests for the diagnosis of latent tuberculosis infection in children and adolescents. Pediatrics, 123, (3), e419-e424. (doi:10.1542/peds.2008-1722). (PMID:19254978).
Spagnolo, Paolo, Richeldi, Luca and du Bois, Roland M. (2008) Environmental triggers and susceptibility factors in idiopathic granulomatous diseases. Seminars in Respiratory and Critical Care Medicine, 29, (6), 610-619. (doi:10.1055/s-0028-1101271). (PMID:19221959).
Ferrara, G., Bleck, B., Richeldi, L., Reibman, J., Fabbri, L.M., Rom, W.N. and Condos, R. (2008) Mycobacterium tuberculosis induces CCL18 expression in human macrophages. Scandinavian Journal of Immunology, 68, (6), 668-674. (doi:10.1111/j.1365-3083.2008.02182.x). (PMID:18959625).
Rossi, Giulio, Andreani, Alessandro, Morandi, Paola, Marchioni, Alessandro, Corradini, Paolo, Cappiello, Gaia, Bortolotti, Monica, Qosja, Ardian, Manzini, Carlo, Ferri, Clodoveo, Richeldi, Luca and Cavazza, Alberto (2008) Eosinophilic globules in bronchoalveolar lavage fluid of patients with systemic sclerosis-related interstitial lung disease: a diagnostically useful, previously unreported finding in a retrospective and prospective study, including differential diagnosis with other idiopathic and secondary interstitial lung diseases. American Journal of Clinical Pathology, 130, (6), 927-933. (doi:10.1309/AJCPJ6W9XOFEXIYS). (PMID:19019770).
Richeldi, L., Bergamini, B.M. and Vaienti, F. (2008) Prior tuberculin skin testing does not boost QuantiFERON-TB results in paediatric contacts. The European Respiratory Journal, 32, (2), 524-525. (doi:10.1183/09031936.00014508 ). (PMID:17215314).
Richeldi, Luca, Losi, Monica, Cerri, Stefania, Casali, Lucio, Fabbri, Leonardo M. and Ferrara, Giovanni (2008) Using ELISpot technology to improve the diagnosis of tuberculosis infection: from the bench to the T-SPOT.TB assay. Expert Review of Respiratory Medicine, 2, (2), 253-260. (doi:10.1586/17476348.2.2.253). (PMID:20477253).
Richeldi, L., Ferrara, G., Fabbri, L.M., Lasserson, T.J. and Gibson, P.G. (2005) Macrolides for chronic asthma. Cochrane Database of Systematic Reviews, 4 (doi:10.1002/14651858.CD002997.pub3). (PMID:16034882).
Voorter, C., Richeldi, Luca, Gervais, T. and van den Berg-Loonen, E. (1998) Identification of two new DPB1 alleles, DPB1*7701 and *7801, by sequence-based typing. Tissue Antigens, 52, (2), 190-192. (doi:10.1111/j.1399-0039.1998.tb02285.x). (PMID:9756410).
Amicosante, M., Richeldi, L., Monno, L., Cuboni, A., Tartoni, P.L., Angarano, G., Orefici, G. and Saltini, C. (1997) Serological markers predicting tuberculosis in human immunodeficiency virus-infected patients. The International Journal of Tuberculosis and Lung Disease, 1, (5), 435-440. (PMID:9441098).
Richeldi, Luca, Kreiss, Kathleen, Mroz, Margaret M., Zhen, Boguang, Tartoni, Pierluigi and Saltini, Cesare (1997) Interaction of genetic and exposure factors in the prevalence of berylliosis. American Journal of Industrial Medicine, 32, (4), 337-340. (PMID:9258386).
Amicosante, M., Richeldi, L., Trenti, G., Paone, G., Campa, M., Bisetti, A. and Saltini, C. (1995) Inactivation of polymerase inhibitors for Mycobacterium tuberculosis DNA amplification in sputum by using capture resin. Journal of Clinical Microbiology, 33, (3), 629-630. (PMID:7751368).
Richeldi, L., Sorrentino, R. and Saltini, C. (1993) HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science, 262, (5131), 242-244. (doi:10.1126/science.8105536). (PMID:8105536).
Amicosante, M., Paone, G., Ameglio, F., Bianchi, E. L., Piccolella, E., Richeldi, L., Bisetti, A., Luisetti, M. and Saltini, C. (1993) Antibody repertoire against the A60 antigen complex during the course of pulmonary tuberculosis. The European Respiratory Journal, 6, (6), 816-822. (PMID:8339800).
Velluti, G., Capelli, O., Richeldi, L., Prandi, E., Lega, M., Rovatti, E. and Covi, M. (1990) Functional activities of human alveolar macrophages. European Respiratory Journal, 3, (3), 361-362. (PMID:2340898).
Capelli, A., Capelli, O., Azzolini, L., Richeldi, L., Prandi, E. and Velluti, G. (1988) Activities of human alveolar macrophages (HAMs), note 1: observations on phagocytosis and bacterial killing in the presence of miocamycin. Chemioterapia, 7, (2), 89-95. (PMID:3260827).
 

Research

The research activities of Luca Richeldi are mainly focused in the area of interstitial lung diseases (ILD), with a particular interest for idiopathic pulmonary fibrosis (IPF).

ILD is a relatively unexplored and rapidly evolving area of respiratory medicine: with more than 200 different clinical entities, these disorders pose a significant challenge in terms of both diagnostic procedures and therapeutic approaches. Patients with ILD represent a major unmet medical need and there is a huge demand for clinical and basic research in this area. In particular, translational approaches seem to be particularly promising and potentially capable of delivering new diagnostic tools combined with effective treatments. The research interests of Luca Richeldi are mainly focused on early diagnosis, biomarkers and effective treatments for ILD.

Computed tomography

Chest high resolution computed tomography of a patient with idiopathic pulmonary fibrosis

Computed tomography

With regard to early diagnosis, he is leading a project exploring the potential of a combination of electronic lung sound detection and chest high resolution computed tomography imaging to achieve a correct diagnosis of ILD, in particular IPF, when the disease is still in a pre-clinical stage. Lung sounds have never been properly assessed in the diagnostic algorithm of ILD patients, although they are still widely used in daily clinical practice. By taking advantage of the possibilities offered by the technology of electronic stethoscopes, this study will tease out potential of automatic acoustic pattern recognition in the early detection of ILD. In combination with the targeted application of chest high-resolution computed tomography, the sensitivity and the specificity of this innovative diagnostic approach will be prospectively evaluated in a multicentre, multinational setting. The study will benefit from the collaboration with the renewed Institute of Sound and Vibration Research at the University of Southampton. It is expected that the results will help to identify patients with ILD at very early stages of their disease, at a time when the effect of drugs slowing down the pathogenetic process in their lung will be maximized.

Reliable biomarkers are one of the missing components in the management of patients with ILD. In particular, the search for reliable, predictive and reproducible non-invasive biomarkers is active at many research centres worldwide. The availability of a reliable biomarker would immensely help in the management of patients with ILD and in the design of clinical trials. Luca is coordinating a multicentre study assessing the reliability and the prognostic value of fibrocytes, circulating in the peripheral blood of patients with IPF: these cells are similar to stem cells and are produced in the bone marrow. Modern flow cytometry techniques allow the identification and the quantification of these cells in small samples of peripheral blood, which can be stored and shipped overnight. It is expected that the results of this study will confirm the feasibility and the usefulness of this non-invasive biomarker in the clinical management of IPF patients.

Until very recently, the therapy for ILD patients has been largely empiric and based on very little scientific evidence. Until recently, a combination of corticosteroid and immunosuppressors has been widely used: however, a controlled clinical trial showed that this combination of drugs is not only ineffective, but most likely harmful inn patients with IPF. Over the last decade an increasing number of drugs have been tested in patients with IPF in the context of properly designed large randomized clinical trials. Luca has been actively involved in most of these trials and he has developed an interest for designing and conducting adequate clinical trials, focusing in particular on the choice of the most relevant clinical endpoints and the most appropriate statistical analyses. In this context, he is also involved in the assessment of comprehensive care for patients with ILD, with a special interest for the development of patient support groups and the use of mindfulness-based stress reduction as a tool to increase the quality of life in this patient population.

Primary research group:  Clinical and Experimental Sciences

Responsibilities

Main Supervisor, PhD programme, Dr. Giacomo Sgalla.

Second supervisor, PhD programme, Dr. Mark Jones.

Contact

Professor Luca Richeldi
Faculty of Medicine
University of Southampton
Southampton General Hospital
Mailpoint 801
South Academic Block
Tremona Road
Southampton
SO16 6YD
or
Faculty of Medicine
University of Southampton
Building 85
Life Sciences Building
Highfield Campus
Southampton
SO171BJ

Room Number: SGH/LF102/MP810

Telephone: (023) 8120 6663
Facsimile: (023) 8051 1761
Email: L.Richeldi@soton.ac.uk